Dr. Fizazi began by revisiting the role of docetaxel in the mHSPC setting, emphasizing that treatment benefit varies ...
(UroToday.com) The 2026 European Association of Urology (EAU) Annual Meeting held in London, U.K., was host to the Hormone sensitive metastatic prostate cancer: Thematic Session. Dr. Declan Murphy ...
SYDNEY, Feb. 16, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that ...
The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being ...
The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing ...
Radiation technologies play a significant role in contemporary human healthcare and extensively used for therapeutic and diagnostic applications in healthcare, especially in cancer care in the country ...
Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the ...
New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of ...
New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...
The most frequent treatment-emergent AEs for belzutifan/lenvatinib were anemia (69.2%), hypertension (58.9%), and diarrhea (52.7%); the cabozantinib arm saw frequent diarrhea (70.1%), hypertension (56 ...
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...
Adding 177Lu-PSMA-617 to ADT and an ARPI maintained health-related quality of life in patients with metastatic hormone-sensitive prostate cancer. The combination of lutetium Lu 177 prostate-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results